Chemotherapy
Articles tagged with Chemotherapy
UT MD Anderson shares latest research breakthroughs
Study may help predict response to chemotherapy in triple-negative breast cancer
Slowly ticking breast cancer cells offer new clues to late relapse
Researchers have identified a hidden mechanism explaining why breast cancer can return years after successful treatment. Slow-growing breast cancer cells can form microscopic tumours that silently tick away in distant organs, evading detection for decades.
UT MD Anderson shares latest research breakthroughs
Researchers at UT MD Anderson Cancer Center have made significant advancements in targeted therapy treatments for advanced lung cancer and early-stage classical Hodgkin lymphoma. The studies showcase high response rates with novel combination therapies and a new understanding of how an enzyme affects infertility and cancer progression.
Researchers find biomarker of chemotherapy resistance in relapsed lung cancer
Researchers have discovered a biomarker for chemotherapy resistance in small cell lung cancer, which can help identify cells that become more invasive and lead to treatment resistance. Targeting these cells with YAP1 may be a possible strategy to improve patient outcomes.
Trial now enrolling seeks to answer key question: Does adding chemotherapy to hormone therapy improve survival for metastatic prostate cancer?
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
Age, sex, and cancer type influence risk of subsequent cancers among survivors
A study published in PLOS Medicine found that age at initial diagnosis, sex, and type of first cancer significantly affect the risk of developing a subsequent primary cancer. Older age and male sex were associated with a higher risk, while survivors of lung, bladder, and skin melanoma were also at increased risk.
Researcher awarded $2.75M NIH grant to develop next-gen cancer treatments
Binghamton University Professor L. Nathan Tumey is working on developing new chemical technologies for antibody-drug-conjugates to push the boundaries of what can be accomplished in ADCs. The goal is to awaken tumor-associated immune cells and prevent cancer regrowth.
Can exercise and ibuprofen lessen cancer-related cognitive impairment?
A Phase II trial found that exercise can improve cognitive function in patients receiving chemotherapy, while low-dose ibuprofen may also have some benefits. The study suggests that exercise is more effective in improving cognitive outcomes, but further research is needed to explore the effects of ibuprofen and combination therapy.
Alliance for Clinical Trials in Oncology supports April Head and Neck Awareness Month
The Alliance for Clinical Trials in Oncology has several active trials specifically designed to help people with head and neck cancers. Trials include testing high-dose prophylactic gabapentin to prevent opioid use during treatment, as well as immunotherapy with nivolumab and cabozantinib for mucosal melanoma and nasopharyngeal carcino...
AACR: UT MD Anderson shares latest breakthroughs in cancer research
Researchers from UT MD Anderson Cancer Center present studies on single-cell technologies, integrative computational approaches, and experimental therapeutics, highlighting innovations in mRNA vaccines and spatial multi-omics techniques. The studies aim to improve immunotherapy responses and detect treatment-resistant glioma cells.
Clinical trial aims to address vaginal complaints after breast cancer diagnosis
A clinical trial aims to evaluate whether laser therapy reduces vaginal dryness caused by breast cancer treatment. The study, REVITALIZE, plans to enroll approximately 250 women with a history of breast cancer who experience moderate to severe vaginal dryness.
Antidepressant unable to prevent chemotherapy-associated nerve damage
A randomized trial found that duloxetine does not prevent painful neuropathy caused by oxaliplatin-based chemotherapy in patients with stage II or III colorectal cancer. The study suggests that duloxetine should only be used for managing existing neuropathy, not prevention.
Are we seeing changes in the rates of secondary blood-related cancers that develop due to chemotherapy or radiation?
A study from Japan has revealed a gradual increase in tAML rates, especially after breast cancer treatment. The study analyzed data from the Osaka Cancer Registry and found that the annual incidence of tAML increased from 0.13 to 0.36 per 100,000 population between 1990 and 2020.
Tumor DNA circulating in patients’ blood after pre-surgery treatments predicts whether breast cancer will return
A study found that tumor DNA in patients' blood can predict whether breast cancer will return, especially after neoadjuvant treatment. Patients with detectable DNA at the end of treatment were 3.5 times more likely to relapse during follow-up.
NUTM1 rearrangements cause a highly treatable form of infant leukemia
Researchers found that NUTM1 rearranged leukemia is distinct from other forms, with decreased DNA methylation and increased lifespan of blood cells. Leukemias with BRD9-NUTM1 fusion are extremely sensitive to chemotherapy, leading to improved clinical outcomes.
Landmark Alliance ATOMIC Trial establishes new standard of care for patients with stage III dMMR colon cancer
The phase III Alliance ATOMIC trial shows that adding immunotherapy to standard chemotherapy improves clinical outcomes for patients with stage III dMMR colon cancer. The study found a 50% reduction in cancer recurrence risk and a 86.3% disease-free survival rate at three years.
New study finds common blood pressure drug boosts cancer treatment
A new study found that the common blood pressure medication telmisartan can significantly enhance the cancer-killing activity of olaparib, potentially expanding its use to many more patients. Telmisartan made tumors more vulnerable to PARP inhibitors, even when they lacked specific DNA repair defects.
Pre-chemotherapy exercise shows promise in reducing cancer-related fatigue
A randomized crossover pilot study found that pre-chemotherapy exercise can reduce cancer-related fatigue and attenuate symptoms. High-intensity interval exercise performed before treatment showed significant benefits on Day 5 post-chemotherapy.
New alliance clinical trial aims to improve outcomes in brain tumors
A new clinical trial will investigate whether adding the oral medication vorasidenib to standard chemotherapy improves progression-free survival for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma. The study aims to recruit 400 individuals with this type of brain cancer and evaluate the safety and side-effect profile of the...
Phase 3 study: New therapy keeps gastrointestinal cancer care on course when low platelets are an obstacle
A phase 3 clinical trial found romiplostim significantly reduced chemotherapy dose delays and improved platelet counts in patients with gastrointestinal cancers who developed persistent low platelet counts during treatment. The therapy enables patients to maintain chemotherapy intensity, potentially preserving the integrity of cancer c...
Researchers break decades-old bottleneck in chemotherapy drug manufacturing
Researchers have identified and resolved molecular bottlenecks to produce doxorubicin, a vital chemotherapy agent, resulting in a 180% increase in production. This breakthrough enables cost-effective manufacturing of essential antibiotics and anti-cancer agents, promising a cleaner and more reliable supply of life-saving medicines.
NRG Oncology/Alliance trial finds immunotherapy did not improve survival when added to chemoradiotherapy for small cell lung cancer
The NRG-LU005 trial found that immunotherapy atezolizumab did not improve survival for patients with limited-stage small cell lung cancer when added to chemoradiation. Twice-daily radiation therapy, however, was associated with improved survival in this population.
Structured exercise programs may help combat “chemo brain” according to new study in JNCCN
Researchers found that patients who followed an exercise prescription while receiving chemotherapy reported fewer problems with thinking and memory and felt less mentally tired. The study suggests that exercise may help people with cancer stay mentally sharp and better able to handle daily tasks.
Romiplostim prevents serious side effect of chemotherapy in phase 3 trial
A phase 3 clinical trial by Mass General Brigham reveals romiplostim's ability to prevent chemotherapy-induced thrombocytopenia, allowing full-dose chemotherapy delivery. The medication boosts bone marrow's resistance to chemotherapy, reducing the risk of life-threatening bleeding and improving cancer treatment outcomes.
Chemotherapy candidate can marshall attention from the body’s natural defenses
Researchers discover a potential chemotherapy agent that causes cancer cells to release signals similar to those released by infected cells, triggering an immune response. This finding could lead to a new approach in cancer treatment, using lower doses of chemotherapy drugs to recruit the immune system as an ally.
Study identifies gene linked to chemotherapy resistance in prostate cancer
Researchers at Weill Cornell Medicine have identified the FOXJ1 gene as a key player in chemotherapy resistance in prostate cancer. The study found that increased FOXJ1 levels in tumors can make cancer cells less responsive to taxane chemotherapy, leading to poorer outcomes for patients.
Alliance for Clinical Trials in Oncology highlights new and open colorectal cancer trials in March
The Alliance for Clinical Trials in Oncology is spotlighting new trials for colorectal cancer in March, focusing on early detection methods and treatments for treatment delays and loss of appetite. The trials aim to improve patient outcomes, with several enrolling patients with newly diagnosed colon or rectal cancer.
Fifteen-year results from SWOG S0016 trial suggest follicular lymphoma is curable
Researchers analyzed 15-year data from a clinical trial, finding that 70% of patients remained alive and 42% were considered cured after treatment. Cure modeling estimated the overall cure rate at 42% of treated patients.
Study: Exercise during chemotherapy for breast cancer measurably improves quality of life
A new study shows that exercise during chemotherapy measurably improves quality of life for women with breast cancer, with benefits consistent across physical, emotional and mental health domains. The findings support existing clinical guidelines and provide clarity on the effectiveness of exercise interventions during treatment.
Singapore study uncovers why some colorectal cancer tumors return and spread after chemotherapy
A Singapore study reveals that a specific gene called SERPINE1 drives resistance to chemotherapy and cancer spread in colorectal cancer patients. The findings also identify a molecular signature called RESIST-M, which can predict poorer survival and higher relapse risk, supporting earlier intervention and more targeted follow-up care.
PAK1 promotes colorectal cancer progression—new insights
Researchers identify PAK1 as a key player in colorectal cancer progression through its ability to stabilize mRNA of oncogenic factors. Targeting PAK1 inhibits proliferation, migration, and invasion, promoting the degradation of these transcripts and sensitizing tumors to standard-of-care treatments.
New JNCCN study identifies long-term health risks among testicular cancer survivors treated with contemporary chemotherapy regimens
A new study published in the Journal of the National Comprehensive Cancer Network (JNCCN) identifies significant long-term health risks among testicular cancer survivors treated with contemporary chemotherapy regimens. Researchers found that survivors treated with etoposide and cisplatin (EPx4) had higher odds of renal impairment, hear...
New biomarker predicts chemotherapy response in triple-negative breast cancer
Researchers developed a new computational approach to predict chemotherapy response in triple-negative breast cancer, outperforming current methods. The TmS biomarker accurately sorts patients into those with favorable or poor prognosis, highlighting its potential as an effective starting point for patient stratification.
Sensing local fibers in pancreatic tumors, cancer cells ‘choose’ to either grow or tolerate treatment
A new study shows that pancreatic cancer cells' ability to detect the extracellular matrix determines their growth rate and response to chemotherapy. The researchers found that cells detecting ECM have low autophagy levels and high growth rates, while those farther away from ECM have high autophagy levels and can survive chemotherapy.
Sylvester Cancer Tip Sheet for Feb. 2026
Researchers at Sylvester Cancer Institute have identified a potential workaround for chemotherapy resistance by blocking a key protein. The study aims to teach lymphoma patients practical tools to manage stress and improve their daily quality of life through the SMART 3RP Lymphoma study. Meanwhile, the institute is expanding cancer dis...
FAU study: Tiny worm offers clues to combat chemotherapy neurotoxicity
Researchers used Caenorhabditis elegans to model chemotherapy-induced neurological dysfunction and tested two compounds for improved recovery. Both sildenafil citrate and Resveramorph-3 significantly reduced seizure-like behaviors and duration, suggesting their potential as therapeutic candidates.
ASH publishes clinical practice guidelines on frontline and relapsed/refractory management of all in adolescents and young adults
The American Society of Hematology released guidelines for frontline and relapsed/refractory management of acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), outlining optimal approaches to treating high-risk patient populations. The guidelines highlight the need for additional research on immunotherapies and tr...
Study: Blocking a key protein may create novel form of stress in cancer cells and re-sensitize chemo-resistant tumors
A new study suggests blocking key protein p300 can create novel form of cellular stress in cancer cells, re-sensitizing chemo-resistant tumors. Cells produce proteins even with damaged DNA, leading to toxic buildup and stress inside the cell's internal quality-control system.
5-FU chemotherapy linked to rare brain toxicity in cancer patient
A rare case of hyperammonemic encephalopathy caused by 5-fluorouracil (5-FU) chemotherapy has been reported, highlighting the importance of monitoring neurological symptoms in patients receiving 5-FU. The patient's symptoms resolved after stopping 5-FU and administering lactulose and intravenous fluids.
GXYLT2: A prognostic biomarker and molecular driver of aggressiveness in gastric cancer
Researchers found GXYLT2 promotes malignant phenotypes in diffuse-type gastric cancer cells, driving tumor progression through Wnt/β-catenin signaling. Targeting GXYLT2 or its downstream axis may provide a novel strategy for improving molecular stratification and therapeutic intervention in gastric cancer.
Study identifies PARG as a new target to enhance chemotherapy in colorectal cancer
A study led by researchers from the Germans Trias i Pujol Research Institute has identified PARG as a new target to enhance chemotherapy in colorectal cancer. Inhibition of PARG significantly increases the cytotoxic effect of chemotherapy, leading to enhanced cell death and apoptosis in different colorectal cancer models.
Clinical trial seeks improved survival for head and neck cancer patients
A new Phase II trial will examine whether giving chemotherapy or chemotherapy combined with immunotherapy before surgery can improve survival compared to surgery alone. The trial aims to identify a treatment that will help patients live longer without the cancer returning.
Chemotherapy rewires gut bacteria to curb metastasis
Research reveals that chemotherapy alters the gut microbiota, producing indole-3-propionic acid, which travels to the bone marrow and rewires immune cell production. This leads to a metastasis-refractory state in preclinical models and improved survival outcomes in patients with colorectal cancer.
Hope for smarter lung cancer care
A study from Flinders University found that patients with progressive disease, which describes the way cancer grows, have varying survival rates depending on whether their existing tumours re-grow or new ones appear. Understanding this progression can help doctors make better decisions about future treatment strategies.
New alliance trial seeks to reduce delays in gastrointestinal cancer treatment
A new clinical trial, PAGODA, seeks to minimize treatment interruptions and help patients complete their chemotherapy as planned. The trial will test a structured plan to guide doctors in making small, proactive changes to chemotherapy doses to prevent treatment delays.
Korea University researchers discover that cholesterol-lowering drug can overcome chemotherapy resistance in triple-negative breast cancer
Researchers found that pitavastatin directly inhibits the anti-apoptotic protein Mcl-1, a key driver of survival and resistance in TNBC cells. The study showed pitavastatin effectively eliminates cancer stem-like cell populations and reduces tumor growth, angiogenesis, and lung metastasis.
Mathematicians tame cellular “noise” to control life at the single-cell level
Researchers create a novel mathematical framework to control biological noise, enabling precise single-cell control. The 'Noise Robust Perfect Adaptation' technology suppresses stochastic fluctuations while maintaining stable average behavior, with promising applications in cancer therapy and synthetic biology.
Enhancer-driven epigenetic rewiring in CBFA2T3-GLIS2 pediatric leukemia
A recent study reveals how the C/G fusion hijacks DNA methylation and chromatin architecture to drive aggressive acute myeloid leukemia in children. The study identifies DNMT3B as a critical effector of the fusion, highlighting its potential as a therapeutic target.
Machine learning drives drug repurposing for neuroblastoma
A study published in EMBO Molecular Medicine has identified a combination of statins and phenothiazines that shows promise in treating aggressive neuroblastoma. The drug combination was found to impede tumour growth and improve survival rates in laboratory trials with mice.
UMBC-led team to study how HIV and cancer drugs harm the brain
Researchers will investigate how HIV and cancer drugs damage brain cells over time, identifying potential early biomarkers of neurotoxicity. They will use human brain organoids grown in the lab to mimic brain physiology.
A platform to test new cancer treatments
Researchers at the University of Geneva have created a laboratory platform to rapidly evaluate the toxicity of new cancer treatments using human tissue-derived cell clusters. This approach allows for safer evaluation and could lead to personalized treatment options.
World-first discovery uncovers how glioblastoma tumours dodge chemotherapy, potentially opening the door to new treatments
Researchers discovered glioblastoma cells use PRDM9 to survive chemotherapy and regrow tumors. By blocking PRDM9 or cutting off cholesterol supply, persister cells can be wiped out, improving survival in mice. This breakthrough offers new strategies for treating the deadliest brain cancer.
Could altering the daily timing of immunotherapy improve survival in people with cancer?
Researchers found that patients who received immunochemotherapy before 3:00 pm experienced significantly longer progression-free survival and overall survival compared to those treated later. Earlier administration of immunotherapy was also associated with lower risks of cancer progression and death.
Antibody halts triple-negative breast cancer in preclinical models
A new study developed an antibody that blocks several ways TNBC cells survive, grow, and evade the immune system. The antibody suppressed primary tumor growth and reenergized cancer-fighting immune cells, including T-cells and macrophages, in preclinical models.
Potential treatment to bypass resistance in deadly childhood cancer
Australian researchers have discovered a drug combination that can bypass the cellular defenses developed by neuroblastoma tumors, making it more effective against relapsed cases. The combination reduces tumor growth and extends survival time compared to standard treatment alone.
Pusan National University researchers identify potential new second-line option for advanced biliary tract cancer
Researchers found that FOLFIRINOX improved progression-free and overall survival in patients with advanced biliary tract cancer. The treatment may offer a benefit as a second-line option after first-line chemotherapy failure, but toxicity remains a concern.
Scientists identify a molecular switch to a painful side effect of chemotherapy
Researchers discover IRE1α pathway in immune cells triggers inflammation and nerve damage after chemotherapy, providing a potential target for prevention and treatment. Biomarkers may help identify patients at risk of developing chemotherapy-induced peripheral neuropathy.
ASTRO publishes first clinical guideline on radiation therapy for gastric cancer
The American Society for Radiation Oncology (ASTRO) has published its first clinical guideline on radiation therapy for gastric cancer. The guidelines provide evidence-based recommendations for the role of radiation therapy in multidisciplinary care, including patient selection, integration with systemic therapy and treatment delivery.